AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
AtriCure Inc. (ATRC) PT Lowered to $53 at BTIG
July 31, 2024 4:58 AM EDTBTIG analyst Marie Thibault lowered the price target on AtriCure Inc. (NASDAQ: ATRC) to $53.00 (from $58.00) while maintaining a Buy rating.
The analyst comments "AtriCure reported Q2 revenue of $116.3M (+15.2% y/y rep, +15.4% y/y cc), in line with consensus of $116.2M. U.S. Q2 revenue was $95.5M (+12.5% y/y), lower than consensus of $97.1M, while International revenue of $20.7M (+29.4% y/y rep, +30.4% y/y cc) beat consensus of $19.0M. The U.S. Appendage Management segment reported $37.9M (+11.8% y/y) in Q2 sales, missing consensus of $38.3M by $400K. However, growth in... More
